Department of Medicine, Section of Cardiology, Wayne State University Medical School, Detroit, MI, USA.
Am J Med. 2011 Sep;124(9):875.e1-9. doi: 10.1016/j.amjmed.2011.04.025.
Supraventricular tachyarrhythmias including atrial fibrillation are common and troubling complications after cardiac surgery, and thus considerable interest in pharmacologic prophylaxis has developed. The aim of this study was to evaluate the efficacy of sotalol in the prevention of postoperative supraventricular tachyarrhythmias.
Standard methods of meta-analysis were used. Randomized clinical trials published in English language were eligible for the meta-analysis.
A systematic review revealed 15 eligible publications that provided 20 comparisons of sotalol with a control group. The incidence and relative risk (RR) with 95% confidence interval (CI) of developing postoperative supraventricular tachyarrhythmias while taking sotalol were sotalol (n=489) versus placebo (n=499): 22.5% versus 41.5%, RR=0.55 (CI, 0.454-0.667, P<.001); sotalol (n=304) versus no treatment (n=311): 12% versus 39%, RR=0.329 (CI, 0.236-0.459, P<.001); sotalol (n=488) versus beta-blocker (n=555): 14% versus 23%, RR=0.644 (CI, 0.495-0.838, P<.001); sotalol (n=139) versus amiodarone (n=146): no significant differences in supraventricular tachyarrhythmia prevention; and sotalol (n=51) versus magnesium (n=54): no significant differences in supraventricular tachyarrhythmia prevention. Initiating sotalol orally or intravenously had no significant effect on efficacy. Initiating sotalol after surgery showed a trend toward less adverse events (before: RR=1.700 [CI, 0.903-3.200] and after: RR=0.767 [CI, 0.391-1.505]).
Sotalol is more effective in the prevention of supraventricular tachyarrhythmia than placebo or beta-blockers. Initiating sotalol before cardiac surgery has no advantage compared with initiating sotalol shortly after surgery. Starting sotalol intravenously after surgery may be a more reliable method than administering via a nasogastric tube or delaying treatment until the patient can take oral medication.
心脏手术后,房性心律失常(包括房颤)是常见且令人困扰的并发症,因此人们对药物预防产生了浓厚的兴趣。本研究旨在评估索他洛尔预防术后房性心动过速的疗效。
采用荟萃分析的标准方法。纳入了以英文发表的随机临床试验。
系统评价显示,有 15 项符合条件的研究提供了 20 项索他洛尔与对照组的比较。服用索他洛尔(n=489)与安慰剂(n=499)发生术后房性心动过速的发生率和相对风险(RR)及其 95%置信区间(CI)分别为:22.5% vs. 41.5%,RR=0.55(CI,0.454-0.667,P<.001);索他洛尔(n=304)与无治疗(n=311):12% vs. 39%,RR=0.329(CI,0.236-0.459,P<.001);索他洛尔(n=488)与β受体阻滞剂(n=555):14% vs. 23%,RR=0.644(CI,0.495-0.838,P<.001);索他洛尔(n=139)与胺碘酮(n=146):预防房性心动过速无显著差异;索他洛尔(n=51)与镁(n=54):预防房性心动过速无显著差异。口服或静脉内给予索他洛尔对疗效无显著影响。术后开始使用索他洛尔有减少不良事件的趋势(术前:RR=1.700[CI,0.903-3.200]和术后:RR=0.767[CI,0.391-1.505])。
与安慰剂或β受体阻滞剂相比,索他洛尔在预防房性心动过速方面更有效。与术后早期开始索他洛尔相比,术前开始使用索他洛尔没有优势。术后静脉内给予索他洛尔可能比通过鼻胃管给药或延迟治疗至患者能够口服药物更可靠。